neurotransmitter reuptake or by blocking the inactivation of intracellular second messengers. These drugs have revolutionized the treatment of human disease. However, the complexity of G protein signaling mechanisms has significantly hampered our ability to identify additional new drug targets. Moreover, today's molecular pharmacologists are accustomed to working on narrowly focused problems centered on a single protein or enzymatic process. Here we describe emerging efforts in yeast aimed at identifying proteins and processes that modulate the function of receptors, G proteins and MAP kinase effectors. The scope of these efforts is far more systematic, comprehensive and quantitative than anything attempted previously, and includes integrated approaches in genetics, proteomics and computational biology.
Mechanism of G protein-mediated signal transduction
The actions of many sensory signals, hormones and neurotransmitters are mediated by cell surface receptors, which have in common a 7-transmembrane topology (7TM receptors or 7TMRs). Receptors of this class are conserved in organisms as diverse as humans, yeasts and plants. They represent the largest gene family in the human genome, and are the target of most pharmaceuticals in use today (Hardman et al., 2001) .
Generally speaking, 7TMRs transmit their signals via G proteins. Upon agonist binding to its receptor, the G protein a subunit releases guanosine diphosphate (GDP), binds guanosine triphosphate (GTP) and dissociates from the G protein bg subunit complex (Sprang, 1997) . Depending on the system, either Ga or Gbg or both can then activate multiple downstream effectors such as adenylyl cyclase, ion channels and phospholipases. In most cases, effector activation occurs at the plasma membrane, but activation results in the production of second messengers (e.g. cAMP or calcium) that diffuse throughout the cell and trigger global changes including protein phosphorylation, new gene transcription and alterations in cell homeostasis or differentiation (Neves et al., 2002) . Other effectors include protein kinase cascades that include members of the mitogenactivated protein kinase (MAPK) family. More recently in mammalian cells, it has been shown that 7TMRs can also signal independently of G proteins, and can instead activate MAPKs through a family of adaptor proteins called arrestins (Shenoy and Lefkowitz, 2005) .
MAPK activation by G proteins can occur through phospholipase Cb, which in turn activates Ras and/or protein kinase C. Either protein can then activate Raf kinase, MAPK kinases, and ultimately a MAPK. Other routes involve activation of the Ras-family members Rac, Cdc42 and Rap. Once activated, the MAPK translocates to the nucleus where it phosphorylates transcription factors, thereby regulating the expression of genes that control cell growth and differentiation (Gutkind, 1998; Marinissen and Gutkind, 2001) .
Less studied are non-nuclear substrates for MAPKs. Only a handful have been identified, but this list includes G protein signaling components such as the GRK receptor kinases and b-arrestin, two classes of proteins that modulate the intensity and specificity of G proteincoupled receptor signaling (Lin et al., 1999; Pitcher et al., 1999) . Regulators of G protein signaling (RGS proteins, described below) are likewise phosphorylated by downstream MAPKs (Garrison et al., 1999; OgierDenis et al., 2000; Parnell et al., 2005) . Thus, the activity of receptors and G proteins may be coordinated in part by the ability of MAPKs to phosphorylate regulatory factors acting throughout the signaling pathway, in both feed-forward and feedback mechanisms.
Ga proteins eventually hydrolyze GTP to GDP, at which point the G protein subunits re-associate and signaling stops. GTPase activity is further accelerated by RGS proteins. So as the specificity of the agonist signal depends on the ability of G proteins to couple only to the appropriate receptor and effector, the intensity of the signal depends on the rates of GTP binding and hydrolysis, events catalyzed by agonist-occupied receptors and RGS proteins, respectively (Neubig and Siderovski, 2002; Chasse and Dohlman, 2003) .
Because of the potential for new pharmacology, an emerging area of investigation is centered on how signal intensity is regulated. Below we describe examples of key regulatory mechanisms acting on the prototypical 7TMR -G protein -MAPK effector cascade. Our emphasis is on the yeast model, but given the extensive structural and functional similarities between yeast and mammalian signaling systems, discoveries made in yeast are generally applicable as well to humans.
G proteins and MAPKs as drug targets
Just as the majority of all clinically important remedies are known to act on G protein-coupled receptors at the cell surface (Hardman et al., 2001) , intracellular signaling proteins represent potentially useful drug targets, particularly in situations where a genetic defect leads to persistent activation by the receptor. Indeed, the clear link between genetic alterations in signaling components and human pathophysiology provides strong evidence that chemical inhibitors of G protein and MAPK signaling could be useful and effective as drugs (Roberts and Der, this issue) . Drugs that inhibit MAPK function could work by interfering with G protein activation, RGS-mediated GTP hydrolysis, second messenger production, MAPK catalytic function, MAPK phosphatase activity or MAPK translocation to the nucleus.
Drug discovery efforts directed at G protein or MAPK signaling components are still in their infancy, but early successes have been reported. Academic labs have identified small molecule inhibitors of RGS proteins (Roman et al., 2006) . Further along in the drug 'pipeline' are small molecule inhibitors of protein kinases. Striking evidence for the potential of protein kinases as drug targets comes from the discovery of imatinib mesylate (Gleevec), an ATP-competitive smallmolecule inhibitor of the Bcr-Abl oncogene product. Treatment with Gleevec can induce complete remissions in the early stages of chronic myelogenous leukemia (Barnes and Melo, 2003) . A major issue in any drug development effort, however, is the identification of appropriate targets for therapeutic intervention. It is not sufficient to know that a particular G protein or protein kinase is activated in a specific disease state, because dysregulation can be the consequence rather than the underlying cause of disease pathology. At the very least, clear genetic or physiological/cell biological data are needed to implicate a protein kinase as a potential target.
Another major issue is selecting which isoform(s) of any given component should be targeted. For example, there are roughly 40 RGS isoforms, each with broad tissue distributions (Gold et al., 1997) . Among the MAPK signaling pathways, candidate targets include at least 11 MAPKs, but there are also another seven MAPK kinases (MAPKKs) and at least 20 MAPK kinase kinases (MAPKKKs). The MAPKs fall into five subfamilies: these are (i) extracellular signal-regulated kinase (ERK)1/2, (ii) c-Jun N-terminal kinase (JNK) 1/2/3, (iii) p38a, b, g and d, (iv) ERK5 and (v) ERK7. Splice variants further contributes to the complexity of selecting appropriate targets. Finally, the broad expression of RGS and MAPKs, and their function in diverse biological responses, suggests that undesired effects and potential toxicity would be observed with inhibitors. Thus, it remains unclear which, if any, of the specific isoforms can be inhibited with useful therapeutic response and lack of adverse effects.
Despite these complications, inhibitors of MAPKrelated processes are in clinical trials or in preclinical development for a variety of cardiovascular diseases, including acute coronary syndromes, stroke, hypertension, diabetes and the metabolic syndrome (reviewed in (Force et al., 2004; Johnson et al., 2005; Sebolt-Leopold and English, 2006) . Inhibitors of p38 have advanced the furthest in clinical trials (Kumar et al., 2003) . Inhibitors of the MAPK kinases MAPK/ERK kinase (MEK)1 and MEK2 are also in clinical trials for the treatment of a variety of tumors. At least one MAPKKK inhibitor (CEP-1347) has advanced to Phase II clinical trials (Roberts and Der, this issue) . Although far from comprehensive, these examples suggest the possibility of future success.
G protein and MAPK signaling in yeast
Yeast genetics in pharmacology research Genetic defects in receptors and Ga proteins have been reported to cause a variety of developmental, metabolic and endocrine disorders (Gutkind, 1998; Farfel et al., 1999; Spiegel, 2000; Marinissen and Gutkind, 2001) . Likewise, dysfunction of MAPK signaling is well known to underlie a broad spectrum of diseases, including many cancers, cardiac hypertrophy, ischemia/reperfusion injury, angiogenesis and atherogenesis (Cuevas, Abell and Johnson, this issue) . The identification of genetic defects in human endocrine disease and cancer has vastly improved our understanding of how G protein and MAPKs act and how they can fail. They can also guide efforts towards new pharmacology. One strategy is to use genetics to identify protein binding partners of a dysfunctional gene product, as any interacting proteins represent alternative (nonmutated) targets for drug therapy (Hartwell et al., 1997) . Another approach has been to screen for second-site mutations that compensate for the primary defect in a gene. For example, we exploited the genetic tractability of the yeast Saccharomyces cerevisiae to identify intragenic suppressors of a GTPase-deficient Ga mutant, Gpa1 Q323L (Apanovitch et al., 1998a) . These second-site suppressor mutations appear to lock the protein in the inactive conformation in both the absence and presence of GTP. Genetic suppression of a disease-causing mutation provides strong presumptive evidence that pharmacological suppression can also be achieved (Gibbs and Oliff, 1994) .
The pheromone/G protein response system in yeast is arguably the best-characterized signaling pathway of any eukaryote, and it has long served as a prototype for hormone, neurotransmitter and sensory response systems in humans. In yeast G protein signaling is required for cell-cell communication leading to mating. Haploid a and a cells secrete type-specific pheromones (a-factor and a-factor, respectively) that promote cell fusion and the formation of an a/a diploid. Most components of the G protein-signaling cascade in yeast were identified genetically, through isolation of mutants that exhibit a mating-deficient (or sterile) phenotype. Among these are genes that encode the pheromone receptor (Ste2), the G protein b and g subunits (Ste4, Ste18), components of a MAPK cascade (Ste20, Ste11, Ste7 and Fus3 or Kss1), a kinase scaffold protein (Ste5) and a transcription factor (Ste12) (Figure 1 ). Fus3 acts primarily in the mating pathway whereas Kss1 acts primarily in the invasive or 'pseudohyphal' growth pathway in nutrient-limited cells. Deletion of both MAPK genes is needed to confer sterility, however, suggesting that Kss1 can function in the place of Fus3 (Dohlman and Thorner, 2001 ).
Dynamic regulation and desensitization
A property of signal-response systems in general, and of G protein-coupled receptors in particular, is that prolonged stimulation leads to desensitization. For mammalian receptors, the mechanisms of desensitization are complex, and include rapid alterations such as phosphorylation by receptor kinases, followed by uncoupling from the G protein and sequestration within minutes of agonist activation (mediated in part by arrestins) (Shenoy and Lefkowitz, 2005) . Receptor desensitization is thought to represent the molecular basis for habituation to light, odors, chemical stimulants and narcotics (Dohlman, 2002) .
Desensitization typically entails some form of feedback inhibition, where a downstream effector alters the activity of an upstream transducer. For example, many cell surface receptors are rapidly phosphorylated and endocytosed following stimulation, and these events limit their ability to transmit the signal. Such phosphorylation-mediated negative feedback mechanisms do not require new protein synthesis and therefore can act rapidly, sometimes within seconds of pathway activation. Other mechanisms can take hours or even days. For instance, negative regulators such as RGS proteins or MAPK phosphatases may be transcriptionally induced. Thus, in any given system there can be multiple overlapping mechanisms of feedback regulation, each with distinct temporal characteristics, that collectively modulate cellular responsiveness to a given stimulus.
Similarly in yeast, prolonged stimulation with mating pheromones eventually leads to desensitization and a resumption of normal cell growth (Dohlman and Thorner, 2001) . Genetic methods in yeast have been used to identify desensitization factors including the first RGS protein Sst2 (Chan and Otte, 1982a, b; Chasse et al., 2006) . Genetic disruption of the SST2 gene has no effect on cell viability but allows cells to respond to concentrations of pheromone at least an order of magnitude lower than in normal cells, and these cells fail to recover from pheromone-induced growth arrest even if the ligand is removed.
With growing appreciation of the similarities between the mammalian and yeast signaling systems, a detailed analysis of Sst2 function was initiated in the mid-1990s. This was done with the expectation -later proven to be correct -that similar proteins must exist in humans. Sst2 Systems biology analysis of yeast N Hao et al was shown to act at the level of the G protein and shown to stimulate Gpa1 GTPase activity, thereby revealing how Sst2 promotes desensitization in yeast (Dohlman et al., 1995 (Dohlman et al., , 1996 Apanovitch et al., 1998b) . Specifically, Sst2 decreases the lifetime of the active form of the G protein, thereby dampening the cellular response to pheromone. Subsequently, more than 40 Sst2 homologs have been identified in mammals, and are now known collectively as the RGS protein family (Neubig and Siderovski, 2002) .
Yeast systems biology
Emerging genomics and proteomics tools in yeast Yeast is well recognized as an excellent model for genetic analysis. Their ability to undergo efficient homologous recombination is particularly useful for studying the functional role of proteins in vivo, through gene disruption or gene replacement. Pheromone stimulation leads to a well-defined series of events required for mating, including readily-assayed responses such as new gene transcription, morphological and cytoskeletal changes, and transient growth arrest in the G1 phase of the cell cycle. As noted above, the yeast system bears strong structural and functional similarity to signaling pathways in mammals. The G-protein and MAPK components in particular share extensive sequence similarity with their human counterparts (Dohlman and Thorner, 2001 ). Yeast has also been a pioneering model system for the development of new proteomic and genomic methodologies. The yeast genome was the first from any eukaryote to be fully sequenced (Goffeau et al., 1996) . Every gene has been arrayed for the purpose of transcription analysis using whole-genome microarrays. Moreover, most yeast genes have now been fused to green fluorescent protein (GFP), fused to a variety of affinity tags (tandem affinity purification (TAP), His6, glutathione-S-transferase (GST)) and deleted (Martzen et al., 1999; Winzeler et al., 1999; Ghaemmaghami et al., 2003; Huh et al., 2003; Gelperin et al., 2005) . Indeed, it is now possible to simultaneously track the expression, localization and activity of nearly every protein within the cell, from the cell surface to the nucleus. Notably, most of the available fusion proteins are expressed at the proper locus and under the control of the native promoter. These strains are all widely available from commercial or academic sources. Case study: systems-level analysis reveals a new signaling pathway in yeast In yeast inactivating mutations in the Ga protein Gpa1 do not block pheromone responses but rather produce a constitutive signal, apparently owing to uncontrolled pathway activation by free Gbg (reviewed in Dohlman and Thorner, 2001 ). These findings provided early evidence that Gbg is necessary and sufficient for mating responses, and that Gpa1 functions primarily to constrain the levels of free Gbg. More recently, however, GTPase-deficient Gpa1 Q323L was shown to initiate (in a dominant manner) many of the same cellular events triggered by mating pheromone and free Gbg, including increased MAPK phosphorylation and new gene transcription (Guo et al., 2003) . Ga-initiated signaling requires the phosphoinositide 3-kinase Vps34 and its regulatory protein Vps15. Gpa1 binds directly to Vps34 and Vps15 in a guanine nucleotide-dependent manner, promotes an increase in phosphoinositide 3-phosphate production, and promotes translocation of phosphoinositide 3-phosphate-binding proteins to the endosome where Vps34 and Vps15 are active. Deletion or pharmacological inhibition of Vps34 abrogates all of these Gpa1 signaling phenotypes (Slessareva et al., 2006) . Thus, genetic, cell biological, biochemical and pharmacological evidence support the model that Vps34 is a direct effector for Gpa1. Notably, Vps15 and Vps34 represent the first additions to this well-studied signaling system in recent memory, and illustrate how there remain many variations of the G protein and MAPK signaling paradigm yet to be fully appreciated.
The identification of Vps15 and Vps34 represents an excellent example of how newly available engineered yeast strains have transformed our approach to signaling research. To identify proteins required for Gpa1-mediated signaling, the GTPase-deficient mutant was introduced into each of approximately 5000 gene deletion strains, along with a transcription-reporter specific for the mating response pathway. Quantitative analysis of transcriptional induction revealed several genes necessary for full Gpa1-mediated signaling, including the phosphoinositide 3-kinase. Moreover, proteins that translocate in response to elevated phosphoinositide 3-phosphate production were identified by systematic microscopy analysis of GFP-fusion proteins (Slessareva et al., 2006) . These findings illustrate how signaling research has evolved to become ever more comprehensive and systematic. If these findings can be extended to mammalian homologs of Vps34 and Vps15, these proteins represent potential new targets for pharmacological modulation of MAPK signaling.
Dynamic regulation of signaling pathways
Above we describe examples of how genomics and proteomics tools can reveal new signaling pathway components. However, interpreting the results of genome-scale studies often relies on traditional models based largely on intuition, often do not consider signaling dynamics, and are rarely quantitative. Different cellular behaviors are commonly regulated by a single G protein or MAPK, but the response may depend on discrete changes in the intensity or duration of enzyme activity. For example, desensitization is commonly defined as 'feedback inhibition after a delay', and as such is an excellent example of dynamic behavior in signaling. Other forms of dynamic behavior are critically important in cell fate decisions. In one oft-cited example, epidermal growth factor promotes transient activation of the ERK MAPK and leads to cell Systems biology analysis of yeast N Hao et al proliferation, whereas nerve growth factor promotes sustained ERK activation and results in cell differentiation (Marshall, 1995) . Thus, a complementary approach to any systematic or systems-level analysis is the development of temporally resolved assays, as well as computational models that consider the temporal behavior of proteins, including dynamic changes in protein activity, localization and expression.
Despite the importance of temporal regulation in signal transduction, the underlying mechanisms leading to pathway inactivation have been especially difficult to define. For G proteins, much recent attention has focused on RGS proteins. With respect to MAPKs, most attention has focused on feedback inhibition through phosphorylation, as well as pathway regulation by protein phosphatases (Morrison and Davis, 2003; Martin et al., 2005) . Phosphorylation is of special interest because it provides a rapid and reversible means for the dynamic control of signaling. Thus, the activity of any MAPK reflects a balance of receptors and RGS proteins, as well as of activating kinases and phosphatases. In the section below, we describe how computational methods may be applied to the study of signaling dynamics.
Modeling cell behavior and signaling dynamics Application of computational methods to biological problems is not new. Indeed receptor theory, which uses mathematical modeling to quantify ligand-induced transitions in the chemical state of the receptor, has been widely used by pharmacologists for over 25 years (Kenakin, 2004) . The 'wiring' of naturally occurring regulatory networks is more complicated, and certainly too complex to rely solely on qualitative descriptions devoid of mathematics. Efforts to model signaling pathways and regulatory networks has lagged, however, despite the availability of appropriate mathematical and computational tools. Early efforts were severely hampered by the lack of suitable experimental data, including insufficient information about the identity and activity (in both space and time) of pathway components. However, new genomics and proteomics tools, as well as a deeper understanding of the underlying biology, have since allowed investigators to reconsider using computational methods to solve complex biological problems.
With respect to G protein and MAPK signaling, early efforts have focused on mechanisms of pathway activation. For example, Yi et al. (2003) modeled the dynamics of G protein activation in the pheromone response pathway of yeast. They used fluorescence resonance energy transfer experiments to measure the association state of the Ga and Gbg subunits. Mathematical modeling was then used to estimate the in vivo rates of G-protein activation and deactivation, in the presence or absence of RGS proteins. Other computational modeling and experimental investigations led to the suggestion that RGS proteins act as kinetic scaffolds (Zhong et al., 2003) . In this model the RGS concentration is uniformly distributed throughout the cell. The accelerated GTPase activity caused by RGS promotes a rapid re-coupling of the G-protein to the receptor. This in turn allows G-proteins to immediately undergo another round of activation. This has the effect of increasing the pool of active G-proteins in the vicinity of receptors, while keeping G-protein activity low elsewhere. In another study Bornheimer et al. (2004) provided a theoretical analysis of the 7TMR-G protein-RGS cycle. They studied signal propagation under various relative concentrations of active receptor, G protein and RGS protein. Their work predicted how changes in component concentrations would lead to distinctive signaling behaviors in terms of steady-state G protein activity and velocity of GTP hydrolysis.
At the level of the effector MAPKs, mathematical modeling revealed that these kinase cascades can be intrinsically 'ultrasensitive', with Hill coefficients as large as 5 (Huang and Ferrell, 1996) . This prediction was confirmed in vitro using Xenopus oocyte extracts (Huang and Ferrell, 1996) . Mathematical modeling also demonstrated that the kinases in MAPK cascades primarily regulate signal amplitude, whereas the phosphatases that mediate pathway deactivation determine signal duration (Heinrich et al., 2002; Hornberg et al., 2005) . These predictions were confirmed by monitoring EGF-induced ERK phosphorylation in the presence of kinase and phosphatase inhibitors (Hornberg et al., 2005) .
In the remainder of this review, we focus on temporal aspects of cell signaling and the mechanisms that regulate pathway activity. We pay particular attention to feedback and feed-forward regulation and illustrate how mathematical modeling has been used to understand the logic of various pathway architectures. We do not consider mathematical modeling of pathway specificity (Somsen et al., 2002; Komarova et al., 2005; Schaber et al., 2006) . Although it is an important topic in cell signaling, the underlying biological mechanisms that dictate signaling specificity are not well established.
Modeling mechanisms of pathway regulation
In this section, we consider five scenarios of pathway regulation. The first two are examples of negative feedback regulation, in which a downstream component modifies the activity of an upstream component resulting in either desensitization or deactivation of the pathway. The third scenario is an example of positive feedback regulation, in which a downstream component promotes further activation of upstream components leading to signal amplification. Finally, we consider two scenarios where upstream components modify the activity of downstream components. Just as the availability of engineered yeast strains has transformed experimental approaches to signaling, there are now several examples of how computational methods have directed experimental approaches. Thus, we provide wherever possible specific examples of each scenario drawn from the yeast model system. Figure 1 ). Hog1 is required for cell adaptation to osmotic stress conditions (Brewster et al., 1993) , and acts by promoting increased production of glycerol that serves to equalize cellular osmotic pressure with the external environment. Yeast mutants that cannot produce or retain glycerol show diminished viability after an osmotic shock, despite strongly enhanced Hog1 phosphorylation. On the other hand, constitutive activation of Hog1 leads to cell death. Therefore, strict control over the dynamics of Hog1 activation is essential for cell survival (Hohmann, 2002; Klipp et al., 2005) . Initially, computational models were devised based on the duration and dose-dependence behavior of Hog1 activity. Given striking differences between pathway activity in the absence and presence of Hog1 catalytic activity, all of the models invoked some Hog1-dependent phosphorylation event. A series of simple mathematical models were fit to the data, and these models suggested the existence of a key phosphorylation event early in the pathway. Further experimental analysis revealed that Hog1 phosphorylates Sho1, and also established that Sho1 exists normally as a homooligomer; moreover, mutation of the phosphorylation site leads to diminished Sho1 oligomerization and diminished signaling (Hao et al., 2007) . These observations led to the model of pathway adaptation shown in Figure 2a . In this model, Sho1 initiates a MAPK cascade that leads to the activation of Hog1, and Hog1 in turn phosphorylates and inhibits Sho1. It is further assumed that Sho1 exists as a homodimer and that feedback phosphorylation causes the dimer to dissociate. Here, we have allowed for the phosphorylation step to be reversible, so that the dephosphorylated Sho1 can reassemble as a dimer and re-enter the signaling pool.
Theoretically speaking, the ability to desensitize the pathway at the level of the 'receptor' has several advantages for the system. First, if there were components shared among multiple signaling pathways (e.g. a common MAPKKK such as Ste11, Figure 1 ), desensitization of the receptor would allow any shared components to remain competent to transmit signals from other receptors. Second, placing multiple pathway components between the MAPK Hog1 and its target of feedback regulation increases the sensitivity of the system. This effect is illustrated in Figure 2b . The blue curve in this figure represents the result when Hog1 is responsible for feedback phosphorylation of the osmosensor Sho1. The red and green curves are the results when the MAPKKK Ste11 and the MAPKK Pbs2, respectively, mediate the feedback phosphorylation of Sho1. This increased sensitivity observed in Figure 2b results from the delay between the feedback phosphorylation event early in the pathway and deactivation of the MAPK late in the pathway. Such a delay would allow the cell to adapt to strong signals yet remain sensitive enough to detect weak signals. Thus, as multicomponent signaling cascades are well known to confer signal amplification, we postulate that multiple components also allow cells to respond appropriately to a wide range of signal strengths without the need for amplification (Hao et al., 2007) .
Scenario 2: negative regulation by feedback deactivation Above we considered a scenario in which the regulated pathway component is transiently removed from the signaling pool. Next, we consider a scenario in which negative feedback causes deactivation of a pathway . This figure indicates that the system is capable of near perfect adaptation. It also shows that using Hog1 (blue) as the negative regulator produces a larger response than if the kinases Ste11 (red) or Pbs2 (green) were responsible for feedback desensitization.
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component, but the deactivated protein is immediately available for reactivation. Figure 3a shows a model in which the stimulus leads to activation of a MAPK. The MAPK then phosphorylates and activates a phosphatase that in turn dephosphorylates the MAPK. At low stimulus levels feedback dephosphorylation is sufficient to restore MAPK activity to near prestimulus levels ( Figure 3b , blue curve). This system does not fully adapt because at steady state a small increase in the level of active MAPK is required to ensure there is enough active phosphatase to counteract the stimulus. As the stimulus level increases the level of active phosphatase eventually saturates, and the MAPK response becomes sustained (Figure 3b, green curve) . If the activation kinetics of the phosphatase are ultrasensitive (Goldbeter and Koshland, 1981) with respect to the active MAPK concentration, then the transition between a transient signal and a sustained signal occurs in a switch-like manner (Figure 3b , inset). For example, a transition from transient to sustained signaling was proposed to underlie MAPK signaling specificity in yeast (Sabbagh et al., 2001) . Feedback desensitization appears to be more common than feedback deactivation. There may be some inherent advantages to the desensitization mechanism, as in this case the sensitivity of the pathway could be increased by making an upstream component of the pathway the target of feedback regulation. However, for the case of feedback deactivation targeting an upstream pathway component diminishes the ability of the system to adapt and makes it susceptible to damped or sustained oscillations (Kholodenko, 2000) . Although biochemical oscillations are well documented in calcium signaling, circadian clocks and cell cycle regulation, a biological example of oscillations in MAPK signaling has not been documented. One possible explanation of this failure to observe oscillations is that it might require single-cell measurements of the activation state of pathway components, which is technically possible but rarely done.
Scenario 3: positive feedback delays pathway activation and produces an irreversible switch We next consider positive feedback mechanisms. Positive feedback can cause a delay in pathway activation, as the stimulus needs only to produce a small increase in pathway activity, and this initial increase is amplified by the positive feedback eventually leading to full pathway activation (Figure 4b , shaded region). One example of such a delay was identified through analysis of the yeast pheromone pathway (Hao et al., 2003) . In this study, functional effects of genetic perturbations on the pathway were examined experimentally and compared with predictions from a model of RGS and G-protein activity Systems biology analysis of yeast N Hao et al the experimental data, including the delay in activation kinetics observed when the RGS protein Sst2 was overexpressed. This suggested the existence of a positive feedback mechanism that counteracts the negative effects of Sst2. This cellular behavior was subsequently found to result from pheromone-promoted ubiquitination and degradation of Sst2. This represents a striking example of how model-driven experiments revealed new mechanisms of cell regulation, which may not have been found by intuitive means alone. Another common feature of positive feedback systems is bistability or 'switch-like' behavior. If the positive feedback is sufficiently strong, it can maintain pathway activity even after the stimulus is removed creating an irreversible switch. This property is particularly important for cell fate decisions such as cell division or differentiation, where it is detrimental to abort the process. Mathematically an irreversible switch occurs when the model equations possess two stable steady state solutions for a single stimulus level. This phenomenon, known as bistability, is demonstrated in Figure 4b . At early times both the stimulus and phospho-MAPK levels are low. When the stimulus level is increased (shaded area in Figure 4b ), the phospho-MAPK concentration increases to a new steady state. When the stimulus is removed the positive feedback is able to maintain phospho-MAPK concentration in an elevated state. Thus at low stimulus levels, the model equations possess two stable steady states corresponding to low and high phospho-MAPK concentrations.
The yeast mating response is one example of such a cell fate decision process. Pheromone activation converts yeast cells from a vegetatively growing state to a growth-arrested state. Growth arrest in G1 and the accompanying morphological changes are pseudo irreversible, as the cell will remain in the arrested state long after the pheromone is removed. Another example of such a cell fate decision process is Xenopus oocyte maturation. In response to the steroid hormone progesterone, oocytes will undergo either maturation and arrest in metaphase of meiosis II or fail to mature and remain arrested in a G2 state. They cannot stay in an intermediate state. Moreover, once an oocyte has matured, it will remain in the mature state even after the progesterone is removed Xiong, 2001, 2003) .
Mathematical modeling has revealed that the dual phosphorylation required for MAPK kinase activation is sufficient to generate bistablility (Markevich et al., 2004) . That is, similar to the results shown in Figure 4 , there is a range of stimulus levels for which there exist two stable concentrations of the dually phosphorylated form of the MAPK. Although biologically this appears to be a case of bistability without positive feedback, mathematically it can be shown that a distributive phosphorylation mechanism, which requires two collisions between the MAPK and MAPK kinase, is equivalent to positive feedback. This mechanism was suggested to underlie the binary response observed in the pheromone response pathway of yeast (Wang et al., 2006) .
Scenario 4: integral control
Perfect adaptation refers to the situation in which a pathway component is only transiently activated despite a persistent stimulus and eventually returns to exactly basal levels. Figure 5a shows a simple model that produces perfect adaptation. In this model a pathway component (e.g. a receptor or protein kinase) is constitutively expressed. The component can exist in two states, the inactive state R and the active state R*. The stimulus increases the rate at which the component transitions to the active state. Subsequent to activation the component becomes desensitized and is removed from the signaling pool. It is important to note that in this model only the active component can be desensitized, desensitization is irreversible and the rate of desensitization is independent of the stimulus strength. Figure 5b shows a time series of the activated component concentration for different stimulus strengths. The stimulus is given at time t ¼ 0 and remains constant for all later times. Note that for all stimulus strengths, the active component concentration returns to its basal levels. This mechanism of adaptation is known as linear integral feedback control (Alon, 2006) , because mathematically it can be shown that the strength of the 'feedback' that restores the timedependent concentration of the activated component R*(t) to its prestimulus level R*(0) is proportional to the integral over time of the difference between R*(0) and R*(t) (i.e., Systems biology analysis of yeast N Hao et al ability to adapt does not depend on the choice of model parameter values (Alon et al., 1999; Alon, 2006) . This integral control mechanism was first proposed to underlie models of bacterial chemotaxis (Alon et al., 1999; Yi et al., 2000) and may contribute as well to signal attenuation of the pheromone response pathway of yeast. Following exposure to pheromone, the MAPK kinase kinase Ste11 rapidly phosphorylates and activates the MAPK kinase Ste7 . Ste11 phosphorylation of Ste7 leads to ubiquitination and increased degradation of the protein (Wang and Dohlman, 2002; Wang et al., 2003) . This mechanism provides a foolproof mechanism for irreversibly depleting the cell of activated signaling components. Depletion of Ste7 might also have detrimental effects, however, because Ste7 is also a component of a second MAPK pathway leading to invasive growth (Figure 1) . Surprisingly, following pheromone stimulation Ste7 levels are roughly equal to their prestimulus levels, implying that yeast have overcome this limitation by concomitant, pheromone-induced production of Ste7. Thus, the net levels of Ste7 remain largely constant, and accelerated degradation is balanced by accelerated synthesis.
Depletion of the signaling pool is one limitation of linear integral feedback control. Another potential drawback is that the duration of the response is almost entirely determined by the rate of desensitization or degradation. Rapid signal attenuation requires rapid turnover of the pathway component. This in turn requires a relatively large constitutive synthesis rate to produce a strong signal. These limitations can be overcome by use of a feed-forward architecture (described below) in which the stimulus activates a parallel pathway that negatively regulates the signal.
Scenario 5: feed-forward regulation A feed-forward architecture refers to a signaling network in which the stimulus initiates parallel pathways that converge on a downstream signaling component. Feed-forward systems can be devised to behave as coincidence detectors, relaying a signal only when both pathways are active, thereby ensuring the pathway is not activated by a spurious or highly transient stimulus (Alon, 2006) . These systems can also be designed to relay a signal when only one of the pathways is active, thereby guarding against a loss of responsiveness if one pathway becomes temporarily inactive (Alon, 2006) . Additionally, if the two parallel pathways have antagonistic effects, this provides another mechanism of perfect adaptation.
Feed-forward regulation may underlie the contribution of the scaffold protein Ste5 to pheromone responses in yeast. Ste5 binds to multiple MAPK kinase components including Ste11, Ste7 and Fus3 (Figure 1 ) and binding to each protein is critical for transmitting signals from membrane-bound G proteins to the cytoplasmic pool of Fus3. The activation of MAPKs requires the recruitment of Ste5-bound MAPK cascade to the plasma membrane through Ste5 binding to Gbg. At the same time, the p21-activated kinase (PAK) Ste20 is activated by membrane-bound Cdc24 and Cdc42. Cdc24 acts as a guanine nucleotide exchange factor for Cdc42, leading to the formation of Cdc42-GTP. Therefore, coincident activation by Gbg and Cdc42-GTP are required to fully activate the MAPK Fus3.
A feed-forward mechanism is likewise thought to underlie transient ERK activation by epidermal growth factor (EGF) (Sasagawa et al., 2005) . Activation of the EGF receptor results in the Son of sevenless homologue protein son of sevenless (SOS) being recruited to the plasma membrane where it acts as a guanine nucleotide exchange factor for Ras, leading to the formation of Ras-GTP. Ras-GTP initiates a cascade eventually leading to MAPK/ERK activation. EGF receptor activation also results in the recruitment of the negative regulator Ras-GAP to the plasma membrane through a slower parallel pathway. In a recent study, Sasagawa et al. (2005) used experimental analysis combined with mathematical modeling to show that this feed-forward mechanism most likely underlies the transient nature of ERK activation by EGF. The fast activation is responsible for the initial accumulation of Ras-GTP and the consequent increase in ERK activation, whereas the slow build up of Ras-GAP causes the signal to quickly decay regardless the continuous presence of EGF. A simplified version of this model is shown in Figure 6 . This system represents the simplest version of perfect adaptation by a feed-forward mechanism (Tyson et al., 2003) .
Signal regulation by multiple control mechanisms Most signaling pathways contain multiple regulatory mechanisms and understanding how these mechanisms are integrated to form a functional signaling system will likely benefit from mathematical modeling. For example, computational analysis of MAPK signaling revealed that the positive feedback loop formed by the MAPK and protein kinase C can generate bistability (Bhalla et al., 2002) . It also demonstrated that the negative effect of a MAPK-induced increase in phosphatase expression moves the signaling network from a bistable state, in which a brief stimulus results in sustained MAPK activation, to a monostable state in which the system responds in a manner proportional to the stimulus. These results were confirmed experimentally and highlight the role of MAPK phosphatases in determining the timing and duration of MAPK activation (Bhalla et al., 2002) . Induction of protein phosphatase expression has likewise been proposed to play a critical role in MAPK signaling in yeast. For example, activation of the MAPKs Fus3 and Hog1 leads to enhanced expression of protein phosphatases, such as the dual-specificity phosphatase Msg5 (acts on Fus3) and the Tyr-specific phosphatases Ptp2 and Ptp3 (Jacoby et al., 1997; Wurgler-Murphy et al., 1997; Roberts et al., 2000) .
We also note that adding a slow negative feedback loop to a bistable system is a common mechanism for generating oscillations. In such a system, when pathway activity is high the negative regulator slowly builds until it is able to drive the pathway back to a state of low Systems biology analysis of yeast N Hao et al activity. This causes expression of the negative regulator to decrease to near basal levels allowing the positive feedback to reactivate the pathway, where the cycle repeats. Such oscillations are referred to as hysteresis oscillations (Tyson et al., 2003) . It was recently shown that when protein degradation is included in a model for the dual phosphorylation cycle of MAPK kinase activation hysteresis oscillations are possible (Wang et al., 2006) . More complex computational models that attempt to capture the behavior of entire signaling pathways are also being developed. For example, Klipp et al. (2005) have constructed a model of the high osmolarity response pathway in yeast mediated by Hog1 (Hohmann, 2002) . Klipp et al. (2005) integrated modeling and experimental approaches to investigate long-term changes in response to osmotic shock, including closing of glycerol channels (preventing the outflow of glycerol upon stress stimulation) and induction of genes required for the biosynthesis of glycerol. Their studies indicate that gene induction is important for maintaining a high level of glycerol production in adapted cells, and when combined with rapid closure of glycerol channels is sufficient to explain an initial glycerol accumulation after osmotic shock. Similar efforts yielded comprehensive models of the yeast pheromone pathway (Kofahl and Klipp, 2004; Shao et al., 2006) and mammalian epidermal growth factor (EGF) receptor pathways (Schoeberl et al., 2002) .
Perspectives
The pharmaceutical industry excels in many endeavors, but has a mixed record of finding truly novel drugs or new drug targets. Much effort is focused on developing second-generation modulators of established targets, and the improvements to health are often incremental at best. The 7TMR class of receptors has been invaluable in drug development. However, the targets for these drugs have been known for 30 or more years. There is now a growing effort to focus pharmacological research on more recently discovered modulators and effectors of 7TMR-controlled signal pathways. The expectation is that pharmacological inhibitors of proteins that modulate 7TMR signaling pathways could be used to control clinically relevant events. Inhibitors that fail to reach the clinic could still serve as valuable research tools, allowing investigators to better define the role of each target in signaling.
Candidate drug targets include arrestins, G proteins, RGS proteins, MAPK components, protein phosphatases or components of the protein degradation machinery. Such drugs could work in a number of ways, such as by interfering with receptor or effector degradation, RGS function, G protein GTP hydrolysis or signal specificity through arrestins versus G proteins. RGS proteins and protein kinases in particular hold tremendous promise as drug targets. It is already established that these proteins play a key role in desensitization, so selective inhibitors could function to enhance the responsiveness of 7TMRs (much like serotonin uptake inhibitors or cGMP phosphodiesterase inhibitors) and their downstream effectors. Finally, RGS proteins and protein kinases appear to act through a variety of other protein-protein (or protein-lipid) interactions mediated by a diverse collection of interaction domains and scaffold proteins; many of which remain to be fully characterized.
Modeling will be especially useful in situations where it is impractical to systematically screen for new pathway inhibitors. By constructing computational models, anticipated outcomes of experimentally feasible perturbations (e.g. pharmacological inhibition or selective knockdown of gene expression) can be tested experimentally and evaluated in the context of the model. With successive rounds of experimentation, modeling and experimental validation, the best mechanisms can be investigated in detail. In this way modeling can serve as a hypothesis generator, helping investigators to best focus their efforts. Mathematical modeling is already being used to understand the physiological changes that occur during oncogenesis. Hornberg et al. (2005) applied control analysis to a detailed model of EGF-induced ERK activation. Their analysis revealed that of the 148 reactions considered in the model, only a small subset Systems biology analysis of yeast N Hao et al significantly controlled the amplitude and duration of ERK activation. In particular, the reactions that were found to have the greatest effect on signal duration and amplitude, were MEK phosphorylation by Raf and Raf dephosphorylation. These results help explain why Raf is such a potent oncogene. Insights gained from modeling will also benefit pharmaceutical research. By quantifying biological systems and accurately predicting cellular processes, it should eventually be possible to direct research into novel pharmaceutical treatments for various diseases. Thus, the use of computational simulations has the potential to radically accelerate the development of modern medicines. Accurate models of feedback regulation in the well-characterized yeast system demonstrates the validity of the approach, and will facilitate similar efforts to model more complex biological pathways in the future.
